CA
NZ
UK
AU
IND
US
ElectroCore, Inc. (NASDAQ: ECOR) appointed Joshua S. Lev and Michael Fox as co-Chief Executive Officers and Presidents, setting both executives’ annual base salaries at $540,000. Lev will retain his role as Chief Financial Officer, while Fox will continue as Chief Operating Officer. The appointments …
After the transaction, Anjaneya held 178,947 derivative securities, while the award represented about 38.2% of that resulting holding.
Evommune, Inc. (NYSE: EVMN) will stop developing EVO756 for atopic dermatitis after the treatment failed to meet the primary and secondary endpoints in its Phase 2b trial. The company will continue evaluating the oral MRGPRX2 antagonist in migraine prophylaxis.
Evommune, Inc. (NYSE: EVMN) plans to cease development of EVO756 for moderate-to-severe atopic dermatitis after its Phase 2b trial did not meet its primary and secondary endpoints at any dose studied. The company’s common stock had a reported sale price of $13.08 per share …
Evotec SE (NASDAQ: EVO) has moved JST-018, an investigational monoclonal-antibody cocktail against orthopoxviruses, into a first-in-human clinical study.
Gossamer Bio, Inc. (NASDAQ: GOSS) plans to reduce its authorized common shares from 4,000,000,000 to 50,000,000 as part of a reverse stock split and related capital-stock reduction. The measure is intended to help the biotechnology company regain compliance with Nasdaq’s minimum bid-price requirement, with …
IQVIA HOLDINGS INC. (NYSE: IQV) is pursuing $2,000,000,000 of senior notes due 2034, giving itsWholly Owned SubsidiaryIQVIA Inc. a new long-datedDebtinstrument. The proceeds are designated for debt repayment and offering-related fees and expenses.
Kura Oncology, Inc. (NASDAQ: KURA) created Caspian Therapeutics to develop next-generation menin inhibitors for diabetes and other cardiometabolic diseases. Caspian raised $50.0 million through the sale of Series A preferred stock, while Kura invested $4.3 million in the financing.
KYNTRA BIO, INC. (NASDAQ: KYNB) CEO Wettig Thane forfeited 209 shares at $8.55 per share. Following the transaction, his reported ownership stood at 26,796 shares.
HBM Healthcare Investments (Cayman) Ltd. reports beneficial ownership of 80,971,680 ordinary shares in Chemomab Therapeutics Ltd. (NASDAQ: CMMB), representing 12.5% of the company’s ordinary shares.
Please wait processing your request...